management

scientific advisory board

board of directors

OUR TEAM

» management

Lissa Goldenstein - President and CEO
Lissa Goldenstein is an entrepreneurial executive with more than 28 years of experience bringing new technology to new markets. Prior to joining Artemis Health, Ms. Goldenstein served as the President and Chief Executive Officer of Argonaut Technologies, Inc (NASDAQ, AGNT) which was sold to Biotage AB of Sweden in June 2005. Prior to her CEO position, Ms. Goldenstein led the commercial activities for Argonaut from 1998, when it was an early stage, venture backed company through its Initial Public Offering in 2000. Argonaut Technologies was the leading provider of instruments and reagents that enable chemists in the pharmaceutical industry to find and develop new drugs. Prior to joining Argonaut, Ms. Goldenstein was Senior Vice President of Worldwide Sales, Marketing and Service with Molecular Simulations Incorporated, the largest provider of molecular modeling software for the pharmaceutical and chemical industries. From 1981 through 1991, Ms. Goldenstein directed sales activities for McDonnell Douglas Corporation, and was responsible for sales of the first CAD/CAM systems sold to designers in the building, engineering and manufacturing industries. Ms. Goldenstein has a B.S. in engineering from Pennsylvania State University. She is currently on the Board of Directors for Artemis Health, Argonaut Technologies and the Las Lomitas Education Foundation.

Melanie M. Mahtani, Ph.D. – Vice President Genetic Diagnostics
Dr. Melanie Mahtani is an experienced executive in the fields of human genetics, biomarker profiling, and personalized approaches to human disease management. Dr. Mahtani founded CompanionDx Consulting, a successful consulting practice for the molecular diagnostics and life science tools industries that provides strategic advisory, business planning and product strategy guidance. Prior to consulting, she was Vice President, Corporate Business Development at Panomics where she led product strategy for multiplexed gene expression products, and strategic partnering activities with major diagnostics, pharmaceutical and biotechnology companies. Dr. Mahtani was previously R&D Director at Amersham Biosciences (now GE Healthcare) where she launched a series of innovative products in high throughput genomic analysis. Dr. Mahtani holds a B.Sc. from Brown University and a Ph.D. in genetics from Stanford University. She was a postdoctoral fellow at the Whitehead Institute and MIT Genome Center where she led whole genome approaches to dissect the genetics of type 2 diabetes and other complex diseases.

Robert Nagle – Vice President Product Development
Mr. Nagle brings extensive product development expertise in microfluidic systems and life science instrumentation. He holds numerous patents in microfluidics, blood analysis and optics. Prior to joining Artemis Health, Mr. Nagle held the positions of Vice President of Product Development with Caliper Technologies and Vice President of Engineering with Turner Biosystems. He has led engineering and development activities for numerous innovative product lines including the first microfluidic systems from Caliper and the Abaxis Piccolo portable blood analyzer. He received his BA in physics from Wesleyan University with Masters and Engineer's degrees from Stanford University.

David Deng, M.D., Ph.D – Director of Assay Development
Dr. Deng is an accomplished scientist with over 10 years experience in molecular research and diagnostic assay development. His expertise includes microfluidics, DNA microarrays and cell biology. Prior to joining Artemis Health, Dr. Deng was with Agilent Technologies where his research efforts focused on biomarker discoveries and clinical diagnostic assay developments. He has numerous peer-reviewed publications and patent applications for nucleic acid analysis and protein separations using microarrays and microfluidics. Dr. Deng is a graduate of Shanghai Second Medical University with an MD and an MS in Immunology and Infectious Disease, and a Ph.D. in Pharmacology from McGill University. He completed his Post-Doctoral Fellowship at University of California San Francisco.

Myla Puyat – Senior Director of Finance and Administration
Ms. Puyat has over 18 years of management experience in Finance, Accounting, Human Resources, Legal and Office Administration ranging from early stage biotech and high-tech startups to Fortune 500 corporations. Prior to joining Artemis Health, Ms. Puyat was the Director of Finance & Administration of ForteBio, Inc. and Controller & Director of Operations of GeneTrol Biotherapeutics, Inc. She has built the infrastructure of many companies from inception through revenue for multiple functional areas. She received both her BS in Computer Engineering and MBA from Santa Clara University.

top

» scientific advisory board

Mehmet Toner, Ph.D.
Dr. Mehmet Toner is a Professor of Bioengineering at the Harvard Medical School and the Director of the Microsystems Bioengineering Laboratory at Massachusetts General Hospital. He received a B.S. degree in Mechanical Engineering from Istanbul Technical University, M.S. degree in Mechanical Engineering from MIT, Ph.D. in Medical Engineering from the Harvard-MIT Division of Health Sciences and Technology. Dr. Toner is internationally recognized in the applications of cell-based microsystems technology in biology and medicine and in tissue engineering and cryopreservation. He has published more than 150 scientific papers in engineering, biological, and clinical journals. Dr. Toner was the recipient of the YC Fung Young Faculty Award in Bioengineering, the Taplin Faculty Fellow Award of Harvard and MIT, and of a fellowship at the American Institute of Medical and Biological Engineering.

Diana W. Bianchi, M.D.
Dr. Diana W. Bianchi is the Natalie V. Zucker Professor of Pediatrics and of Obstetrics and Gynecology at Tufts University School of Medicine, and Vice-Chair for Research, Department of Pediatrics. A native of Manhattan, Dr. Bianchi graduated magna cum laude from the University of Pennsylvania. She received her M.D. from Stanford University and her residency training in pediatrics at The Children’s Hospital, Boston. She then completed fellowships in the Harvard training programs in medical genetics and newborn medicine and is board-certified in all three specialties. Dr. Bianchi has authored over 165 peer-reviewed clinical and research publications. Along with Timothy Crombleholme and Mary D’Alton she co-authored the textbook, Fetology: Diagnosis and Management of the Fetal Patient, which won the Association of American Publishers award for best textbook in clinical medicine in 2000, and has been translated into Japanese. She is an Associate Editor of the journal Prenatal Diagnosis. Dr. Bianchi is recognized locally, nationally and internationally for her leadership roles. She is a trustee of Tufts-New England Medical Center. Her national/international committee assignments and elected offices include Scientific Program Chair for the 2002 American Society of Human Genetics annual meeting, Board Member of the American Society of Human Genetics, Secretary of the International Society for Prenatal Diagnosis, and Council member (Genetics) in the Society for Pediatric Research. She is a past president of the Perinatal Research Society, a member of the American Pediatric Society and current president of the International Society for Prenatal Diagnosis. She has been awarded the Distinguished Faculty Award from Tufts University and was named an honorary member of the Society for Maternal Fetal Medicine and the American Pediatric Surgical Association.

Ronald G. Tompkins, M.D., ScD
Dr. Ronald Tompkins is the John Francis Burke Professor of Surgery at the Harvard Medical School, the Chief of the Trauma, Burns & Surgical Critical Care Service of the Massachusetts General Hospital (MGH), and the Chief of Staff of the Shriners Hospitals for Children-Boston. He received a B.S. degree in Chemistry from Tulane University, an M.D. degree from Tulane Medical School, and a ScD degree in medical and chemical engineering from the Massachusetts Institute of Technology (MIT). Dr. Tompkins has served on scores of national committees and received multiple honors including a fellowship from the American Institute for Medical and Biological Engineering and an honorary M.A. from Harvard University, and he is a senior director of the American Board of Surgery. Dr. Tompkins has published more than 250 contributions to the medical literature. His research interests include the metabolic and inflammatory responses to injury and tissue engineering.

Martin A. Schmidt, Ph.D.
Dr. Martin Schmidt is a Professor in the MIT Department of Electrical Engineering and Computer Science, and the Director of the MIT Microsystems Technology Laboratory (MTL). He received a B.S. degree in Electrical Engineering from Rensselaer Polytechnic Institute, and M.S. and Ph.D. degrees in Electrical Engineering from MIT. Dr. Schmidt is an internationally recognized leader in microsystems engineering, in general, and its applications in biology, in particular. He has organized and chaired many international meetings in the general area of micro-sensors and actuators, microtonal analysis systems, and bio-microelectromechanical systems. He has extensively published his technological developments in prestigious journals, including the Journal of Microelectromechanical Systems, Journal of Biomechanical Engineering, and Biophysical Journal.

Ronald W. Davis, Ph.D.
Dr. Ronald Davis is a Professor of Genetics and Biochemistry at Stanford University and the Director of the Stanford Genome Technology Center. He received a B.S. in Chemistry from Eastern Illinois University, and a Ph.D. in Chemistry from California Institute of Technology. He is the recipient of many international and national awards for his contributions to genetics research and technology development related to genomics and proteomics. Among his awards: the United States Steel Award, Louis S Rosentiel Award for Distinguished Work in Basic Biomedical Research, Genetics Society of America Award, and Chiron Biotechnology Research Award. He was elected to the National Academy of Sciences (Genetics) in 1983. Dr. Davis is a leader in the development and application of many critical technologies utilized in genomics and proteomics research. He is also a world leader in the burgeoning field of single nucleotide polymorphisms (SNPs).

top

» board of directors

Bill Ericson
Bill Ericson joined Mohr Davidow Ventures in 2000. As a managing partner, his investment focus is life sciences and software. He works closely with a cross-discipline team of leading scientists, researchers and entrepreneurs applying technology solutions to life sciences and health care in non-traditional ways. Mr. Ericson came to MDV after 10 years of working with and investing in entrepreneurs and early stage companies. During that time, he served as a board member of a number of life sciences and software companies, both public and private. Bill was a member of the founding team of Rosetta Inpharmatics and served on the Board of Directors until its acquisition by Merck in 2001.

Michael Hunkapiller, PhD.
Michael Hunkapiller joined Alloy in 2004 after 21 years at Applied Biosystems (NYSE: ABI), which he helped grow from startup to almost $2 billion in annual revenues supplying instrument and reagent systems for life science research. At ABI, he held several positions, most recently as President and General Manager. He was also a founder of ABI's sister company Celera Genomics (NYSE: CRA) and Senior Vice President of Applera Corporation (their parent company). Prior to joining ABI, Mike was a senior research fellow in the Division of Biology at the California Institute of Technology. He received a B.S. in Chemistry from Oklahoma Baptist University in 1970 and a Ph.D. in Chemical Biology from the Division of Chemistry and Chemical Engineering at Caltech in 1974. He has authored more than 100 scientific publications, is an inventor on more than two dozen patents, and has served on the editorial boards of several scientific journals. He has received several awards for his contributions to life science research, including the development of the automated DNA sequencing systems used to sequence the human genome. Mike is currently on the board of directors of Codon Devices, Fluidigm, and Pacific Biosciences.

James B. Powell, M.D.
Jim Powell has a proven track record of bringing innovative clinical products to market. Currently he is President and Medical Director of Paladin Laboratories, LLC. From 1999-2000, Jim was President and CEO of TriPath Imaging, Inc. (NASDAQ: TPTH). Prior to that, from 1997-1999, Jim was President and CEO of AutoCyte, Inc (NASDAQ: ACYT). He was President and CEO of Laboratory Corporation of America (NYSE: LABCORP) from 1995-1997. Jim was President and CEO of Roche Biomedical Laboratories from 1982-1995, after selling Biomedical Reference Laboratories (NASDAQ: BRL) a company he founded in 1972, to Hoffmann-La Roche in 1982. Jim received a B.A. in Biology from the Virginia Military Institute and an M.D. from Duke University. Following medical school, he did a pathology residency and cytopathology fellowship at Cornell University Medical Center and a pathology residency at Englewood Hospital. Jim spent the next three years as a Major in the US Medical Corp at Walter Reed Army Institute of Research.

top